http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 24 Feb 2026 10:12:58 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Increasing+unusual+put+option+volume%3A++ALDX+SMMT+FIS+KLAR+WHR+LNC+UL+IGV+XBI+SGHC+DLR+SOLT+/26048676.html <p>Increasing unusual put option volume: ALDX SMMT FIS KLAR WHR LNC UL IGV XBI SGHC DLR SOLT</p> http://www.streetinsider.com/Options/Increasing+unusual+put+option+volume%3A++ALDX+SMMT+FIS+KLAR+WHR+LNC+UL+IGV+XBI+SGHC+DLR+SOLT+/26048676.html Tue, 24 Feb 2026 10:12:58 -0500 XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html <p>RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.</p><p>Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.</p><p>“With sentiment clearly improving, 3Q looking solid with very few potential disappointments, much http://www.streetinsider.com/Hot+List+Pro/Biotech+stocks%3A+Q3+earnings+preview/25446134.html Sun, 12 Oct 2025 15:00:00 -0500 ACAD ALNY ASND BIIB GILD LEGN NBIX ONC VRTX XBI http://www.streetinsider.com/Options/SPDR+S%26P+Biotech+ETF+%28XBI%29+options+active+option+volume+of+120K+contracts/25408815.html <p>SPDR S&P Biotech ETF (NYSE: XBI) 30-day option implied volatility is at 27; compared to its 52-week range of 24 to 62 on active option volume of 120K contracts.</p> http://www.streetinsider.com/Options/SPDR+S%26P+Biotech+ETF+%28XBI%29+options+active+option+volume+of+120K+contracts/25408815.html Thu, 02 Oct 2025 04:47:51 -0500 XBI http://www.streetinsider.com/Trader+Talk/Trump%3A+Will+Be+Reducing+Drug+Prices+By+1400%25-1500%25/25245643.html <p>Trump: Will Be Reducing Drug Prices By 1400%-1500%</p> http://www.streetinsider.com/Trader+Talk/Trump%3A+Will+Be+Reducing+Drug+Prices+By+1400%25-1500%25/25245643.html Mon, 25 Aug 2025 12:03:45 -0500 XBI http://www.streetinsider.com/Trader+Talk/White+House%3A+Trump+took+action+on+pharma+Thursday%2C+sent+letters+to+CEOs/25129024.html (Updated - July 31, 2025 1:38 PM EDT) <p>White House: Trump took action on pharma Thursday, sent letters to CEOs</p><ul><li>White House: letters sent to 17 major drug and pharma companies in U.S.</li><li>White House: Trump tells pharma execs to extend most favored nation pricing to Medicaid, guarantee it for new drugs, and provide it for direct purchasing<br /></li></ul> http://www.streetinsider.com/Trader+Talk/White+House%3A+Trump+took+action+on+pharma+Thursday%2C+sent+letters+to+CEOs/25129024.html Thu, 31 Jul 2025 13:38:25 -0500 AMGN AZN BMY LLY PFE REGN TEVA XBI http://www.streetinsider.com/Trader+Talk/White+House%3A+Trump+took+action+on+pharma+Thursday%2C+sent+letters+to+CEOs/25129024.html (Updated - July 31, 2025 1:38 PM EDT) <p>White House: Trump took action on pharma Thursday, sent letters to CEOs</p><ul><li>White House: letters sent to 17 major drug and pharma companies in U.S.</li><li>White House: Trump tells pharma execs to extend most favored nation pricing to Medicaid, guarantee it for new drugs, and provide it for direct purchasing<br /></li></ul> http://www.streetinsider.com/Trader+Talk/White+House%3A+Trump+took+action+on+pharma+Thursday%2C+sent+letters+to+CEOs/25129024.html Thu, 31 Jul 2025 13:38:25 -0500 AMGN AZN BMY LLY PFE REGN TEVA XBI